Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population.
antimicrobial stewardship program
antimicrobials
defined daily dose (DDD)
pediatric
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
10
01
2023
revised:
23
01
2023
accepted:
29
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumption indicator. However, there are no DDDs adapted to the pediatric population. The main objective of this study is to establish the most appropriate DDD values in this population. An observational, retrospective, multicenter study was conducted. Antimicrobial prescriptions were collected from pediatric wards of seven Spanish tertiary hospitals for 2 years. The DDDs obtained from the prescriptions were compared with the theoretical DDDs agreed upon in the first stage. To select the optimal DDD, the following were analyzed: power value, magnitude obtained from the differences in the DDD, statistical significance, and degree of agreement in the stipulated doses. A total of 4788 prescriptions were collected. Pediatric DDD was defined for 30 different antimicrobials. A potency >80% was obtained in 24 antibiotics. 51.2% of the selected DDD correspond to Phase I and 39.5% from Phase II. Pediatric DDD of different antimicrobials was obtained, providing an indicator that can be used globally in different hospitals to analyze the consumption and efficacy of ASPs.
Identifiants
pubmed: 36830187
pii: antibiotics12020276
doi: 10.3390/antibiotics12020276
pmc: PMC9952639
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : CM21/00115
Références
J Antimicrob Chemother. 2012 May;67(5):1278-86
pubmed: 22378680
Enferm Infecc Microbiol Clin. 2017 Nov;35(9):556-562
pubmed: 28284685
Sci Rep. 2021 Feb 11;11(1):3543
pubmed: 33574450
Enferm Infecc Microbiol Clin (Engl Ed). 2019 May;37(5):301-306
pubmed: 30268590
J Antimicrob Chemother. 2011 Feb;66(2):443-9
pubmed: 21084362
Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1301-3
pubmed: 20556467
Acta Paediatr. 2015 Jul;104(7):687-92
pubmed: 25753620
Pediatr Investig. 2021 Sep 22;5(3):229-238
pubmed: 34589677
Adv Exp Med Biol. 2015;835:45-51
pubmed: 25252896
Pediatr Infect Dis J. 2013 Jun;32(6):e242-53
pubmed: 23838740
Lancet Infect Dis. 2010 Mar;10(3):167-75
pubmed: 20185095
Discoveries (Craiova). 2020 Dec 10;8(4):e119
pubmed: 33365385
Clin Microbiol Infect. 2009 Apr;15 Suppl 3:12-5
pubmed: 19366364
J Antimicrob Chemother. 2010 Oct;65(10):2247-52
pubmed: 20713405
Lancet Infect Dis. 2022 Dec 22;:
pubmed: 36566768
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Enferm Infecc Microbiol Clin. 2013 Sep;31 Suppl 4:16-24
pubmed: 24129285
Infect Dis Clin North Am. 2014 Jun;28(2):195-214
pubmed: 24857388
Clin Microbiol Infect. 2020 Mar;26(3):358-365
pubmed: 31323260
Pediatr Infect Dis J. 2015 Mar;34(3):311-3
pubmed: 25584443
Clin Infect Dis. 2022 Oct 21;:
pubmed: 36268822
Farm Hosp. 2021 Feb 22;45(2):82-88
pubmed: 33709892